Summary of the first international gastrointestinal eosinophil research symposium

Chris A. Liacouras, Peter Bonis, Phil E. Putnam, Alex Straumann, Eduardo Ruchelli, Sandeep Gupta, James J. Lee, Simon P. Hogan, Barry K. Wershil, Marc E. Rothenberg, Steven J. Ackerman, Ignatius Gomes, Simon Murch, Anil Mishra, Glenn T. Furuta

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The recent explosion of literature and increasing clinical experiences have established EE as a chronic disease. Few patients, if any, outgrow their illness. As such, a number of clinical management issues and basic research questions have emerged. Although the First International Gastrointestinal Eosinophil Researcher Symposium provided much in the way of clinical advice and new knowledge, it also raised important questions that will take time to answer: Etiology and pathogenesis Maintenance treatment strategies Endpoints for treatment Natural history and complications Optimalmethod to identify food antigens/aeroallergens Methods to differentiate eosinophilia associated with GERD and EE Noninvasive technologies to assess disease activity Evaluation and management of asymptomatic patient with esophageal eosinophilia The most pressing clinical issues focus on the natural history of the disease and the necessity and determination of appropriate maintenance treatments. These areas are undeniably linked; if patients are free from long-term morbidity, then the importance of chronic treatments is diminished. This scenario does not appear to be the case for most patients who experience a waxing and waning course that can affect daily life in an untoward manner. As more physicians recognize the chronicity of the disease, a larger body of experience dictates that complications and long-term problems may arise. Although strictures and narrow-caliber esophagus are the bestknown sequelae in adults, EE is certainly associated with a less well-defined but clinically important impact on a child's eating behavior. Along these same lines, the best treatment endpoint has yet to be determined. To date, research protocols have focused primarily on tissue eosinophilia as an endpoint because many clinicians are somewhat reluctant to leave the esophagus with any degree of inflammation. Using clinical phenotypes (allergic vs nonallergic) along with noninvasive or mucosal biomarker profiles (ie, eotaxin-3, IL-5) may hold promise for future identification of patients who will benefit, or not, from more targeted therapeutic intervention and monitoring. For example, the suggestion that there may be allergic and nonallergic phenotypes may guide future treatment into different approaches (nutritional vs medical). Each of these areas demands careful documentation and basic studies to know the mechanisms by which eosinophils affect the esophageal mucosa. Eight years ago, Dr David Landon made the following observation: "My suspicion is that some EEs evolve into the fibrotic variety. Only one of these has reversed on fluticasone. The problem would seem to be that once fibrosis becomes truly established, the disease seems irreversible. Whether other therapy, or a more basic attack, would change this outcome, I don't know." As collaborative basic and clinical research projects continue to address these unresolved problems, we will gain increasing clarity as to the best manner in which to provide immediate and long-term care for our patients.

Original languageEnglish
Pages (from-to)370-391
Number of pages22
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume45
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

eosinophils
Eosinophils
eosinophilia
endpoints
Research
Eosinophilia
esophagus
Therapeutics
digestive tract mucosa
long term care
Esophagus
phenotype
interleukin-5
therapeutics
complications (disease)
explosions
research projects
fibrosis
Phenotype
chronic diseases

ASJC Scopus subject areas

  • Gastroenterology
  • Histology
  • Medicine (miscellaneous)
  • Food Science
  • Pediatrics, Perinatology, and Child Health

Cite this

Summary of the first international gastrointestinal eosinophil research symposium. / Liacouras, Chris A.; Bonis, Peter; Putnam, Phil E.; Straumann, Alex; Ruchelli, Eduardo; Gupta, Sandeep; Lee, James J.; Hogan, Simon P.; Wershil, Barry K.; Rothenberg, Marc E.; Ackerman, Steven J.; Gomes, Ignatius; Murch, Simon; Mishra, Anil; Furuta, Glenn T.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 45, No. 3, 09.2007, p. 370-391.

Research output: Contribution to journalArticle

Liacouras, CA, Bonis, P, Putnam, PE, Straumann, A, Ruchelli, E, Gupta, S, Lee, JJ, Hogan, SP, Wershil, BK, Rothenberg, ME, Ackerman, SJ, Gomes, I, Murch, S, Mishra, A & Furuta, GT 2007, 'Summary of the first international gastrointestinal eosinophil research symposium', Journal of Pediatric Gastroenterology and Nutrition, vol. 45, no. 3, pp. 370-391. https://doi.org/10.1097/MPG.0b013e318142b4f8
Liacouras, Chris A. ; Bonis, Peter ; Putnam, Phil E. ; Straumann, Alex ; Ruchelli, Eduardo ; Gupta, Sandeep ; Lee, James J. ; Hogan, Simon P. ; Wershil, Barry K. ; Rothenberg, Marc E. ; Ackerman, Steven J. ; Gomes, Ignatius ; Murch, Simon ; Mishra, Anil ; Furuta, Glenn T. / Summary of the first international gastrointestinal eosinophil research symposium. In: Journal of Pediatric Gastroenterology and Nutrition. 2007 ; Vol. 45, No. 3. pp. 370-391.
@article{f18ca7be2cec4fd8899271cf5fe4b5b6,
title = "Summary of the first international gastrointestinal eosinophil research symposium",
abstract = "The recent explosion of literature and increasing clinical experiences have established EE as a chronic disease. Few patients, if any, outgrow their illness. As such, a number of clinical management issues and basic research questions have emerged. Although the First International Gastrointestinal Eosinophil Researcher Symposium provided much in the way of clinical advice and new knowledge, it also raised important questions that will take time to answer: Etiology and pathogenesis Maintenance treatment strategies Endpoints for treatment Natural history and complications Optimalmethod to identify food antigens/aeroallergens Methods to differentiate eosinophilia associated with GERD and EE Noninvasive technologies to assess disease activity Evaluation and management of asymptomatic patient with esophageal eosinophilia The most pressing clinical issues focus on the natural history of the disease and the necessity and determination of appropriate maintenance treatments. These areas are undeniably linked; if patients are free from long-term morbidity, then the importance of chronic treatments is diminished. This scenario does not appear to be the case for most patients who experience a waxing and waning course that can affect daily life in an untoward manner. As more physicians recognize the chronicity of the disease, a larger body of experience dictates that complications and long-term problems may arise. Although strictures and narrow-caliber esophagus are the bestknown sequelae in adults, EE is certainly associated with a less well-defined but clinically important impact on a child's eating behavior. Along these same lines, the best treatment endpoint has yet to be determined. To date, research protocols have focused primarily on tissue eosinophilia as an endpoint because many clinicians are somewhat reluctant to leave the esophagus with any degree of inflammation. Using clinical phenotypes (allergic vs nonallergic) along with noninvasive or mucosal biomarker profiles (ie, eotaxin-3, IL-5) may hold promise for future identification of patients who will benefit, or not, from more targeted therapeutic intervention and monitoring. For example, the suggestion that there may be allergic and nonallergic phenotypes may guide future treatment into different approaches (nutritional vs medical). Each of these areas demands careful documentation and basic studies to know the mechanisms by which eosinophils affect the esophageal mucosa. Eight years ago, Dr David Landon made the following observation: {"}My suspicion is that some EEs evolve into the fibrotic variety. Only one of these has reversed on fluticasone. The problem would seem to be that once fibrosis becomes truly established, the disease seems irreversible. Whether other therapy, or a more basic attack, would change this outcome, I don't know.{"} As collaborative basic and clinical research projects continue to address these unresolved problems, we will gain increasing clarity as to the best manner in which to provide immediate and long-term care for our patients.",
author = "Liacouras, {Chris A.} and Peter Bonis and Putnam, {Phil E.} and Alex Straumann and Eduardo Ruchelli and Sandeep Gupta and Lee, {James J.} and Hogan, {Simon P.} and Wershil, {Barry K.} and Rothenberg, {Marc E.} and Ackerman, {Steven J.} and Ignatius Gomes and Simon Murch and Anil Mishra and Furuta, {Glenn T.}",
year = "2007",
month = "9",
doi = "10.1097/MPG.0b013e318142b4f8",
language = "English",
volume = "45",
pages = "370--391",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Summary of the first international gastrointestinal eosinophil research symposium

AU - Liacouras, Chris A.

AU - Bonis, Peter

AU - Putnam, Phil E.

AU - Straumann, Alex

AU - Ruchelli, Eduardo

AU - Gupta, Sandeep

AU - Lee, James J.

AU - Hogan, Simon P.

AU - Wershil, Barry K.

AU - Rothenberg, Marc E.

AU - Ackerman, Steven J.

AU - Gomes, Ignatius

AU - Murch, Simon

AU - Mishra, Anil

AU - Furuta, Glenn T.

PY - 2007/9

Y1 - 2007/9

N2 - The recent explosion of literature and increasing clinical experiences have established EE as a chronic disease. Few patients, if any, outgrow their illness. As such, a number of clinical management issues and basic research questions have emerged. Although the First International Gastrointestinal Eosinophil Researcher Symposium provided much in the way of clinical advice and new knowledge, it also raised important questions that will take time to answer: Etiology and pathogenesis Maintenance treatment strategies Endpoints for treatment Natural history and complications Optimalmethod to identify food antigens/aeroallergens Methods to differentiate eosinophilia associated with GERD and EE Noninvasive technologies to assess disease activity Evaluation and management of asymptomatic patient with esophageal eosinophilia The most pressing clinical issues focus on the natural history of the disease and the necessity and determination of appropriate maintenance treatments. These areas are undeniably linked; if patients are free from long-term morbidity, then the importance of chronic treatments is diminished. This scenario does not appear to be the case for most patients who experience a waxing and waning course that can affect daily life in an untoward manner. As more physicians recognize the chronicity of the disease, a larger body of experience dictates that complications and long-term problems may arise. Although strictures and narrow-caliber esophagus are the bestknown sequelae in adults, EE is certainly associated with a less well-defined but clinically important impact on a child's eating behavior. Along these same lines, the best treatment endpoint has yet to be determined. To date, research protocols have focused primarily on tissue eosinophilia as an endpoint because many clinicians are somewhat reluctant to leave the esophagus with any degree of inflammation. Using clinical phenotypes (allergic vs nonallergic) along with noninvasive or mucosal biomarker profiles (ie, eotaxin-3, IL-5) may hold promise for future identification of patients who will benefit, or not, from more targeted therapeutic intervention and monitoring. For example, the suggestion that there may be allergic and nonallergic phenotypes may guide future treatment into different approaches (nutritional vs medical). Each of these areas demands careful documentation and basic studies to know the mechanisms by which eosinophils affect the esophageal mucosa. Eight years ago, Dr David Landon made the following observation: "My suspicion is that some EEs evolve into the fibrotic variety. Only one of these has reversed on fluticasone. The problem would seem to be that once fibrosis becomes truly established, the disease seems irreversible. Whether other therapy, or a more basic attack, would change this outcome, I don't know." As collaborative basic and clinical research projects continue to address these unresolved problems, we will gain increasing clarity as to the best manner in which to provide immediate and long-term care for our patients.

AB - The recent explosion of literature and increasing clinical experiences have established EE as a chronic disease. Few patients, if any, outgrow their illness. As such, a number of clinical management issues and basic research questions have emerged. Although the First International Gastrointestinal Eosinophil Researcher Symposium provided much in the way of clinical advice and new knowledge, it also raised important questions that will take time to answer: Etiology and pathogenesis Maintenance treatment strategies Endpoints for treatment Natural history and complications Optimalmethod to identify food antigens/aeroallergens Methods to differentiate eosinophilia associated with GERD and EE Noninvasive technologies to assess disease activity Evaluation and management of asymptomatic patient with esophageal eosinophilia The most pressing clinical issues focus on the natural history of the disease and the necessity and determination of appropriate maintenance treatments. These areas are undeniably linked; if patients are free from long-term morbidity, then the importance of chronic treatments is diminished. This scenario does not appear to be the case for most patients who experience a waxing and waning course that can affect daily life in an untoward manner. As more physicians recognize the chronicity of the disease, a larger body of experience dictates that complications and long-term problems may arise. Although strictures and narrow-caliber esophagus are the bestknown sequelae in adults, EE is certainly associated with a less well-defined but clinically important impact on a child's eating behavior. Along these same lines, the best treatment endpoint has yet to be determined. To date, research protocols have focused primarily on tissue eosinophilia as an endpoint because many clinicians are somewhat reluctant to leave the esophagus with any degree of inflammation. Using clinical phenotypes (allergic vs nonallergic) along with noninvasive or mucosal biomarker profiles (ie, eotaxin-3, IL-5) may hold promise for future identification of patients who will benefit, or not, from more targeted therapeutic intervention and monitoring. For example, the suggestion that there may be allergic and nonallergic phenotypes may guide future treatment into different approaches (nutritional vs medical). Each of these areas demands careful documentation and basic studies to know the mechanisms by which eosinophils affect the esophageal mucosa. Eight years ago, Dr David Landon made the following observation: "My suspicion is that some EEs evolve into the fibrotic variety. Only one of these has reversed on fluticasone. The problem would seem to be that once fibrosis becomes truly established, the disease seems irreversible. Whether other therapy, or a more basic attack, would change this outcome, I don't know." As collaborative basic and clinical research projects continue to address these unresolved problems, we will gain increasing clarity as to the best manner in which to provide immediate and long-term care for our patients.

UR - http://www.scopus.com/inward/record.url?scp=34548684111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548684111&partnerID=8YFLogxK

U2 - 10.1097/MPG.0b013e318142b4f8

DO - 10.1097/MPG.0b013e318142b4f8

M3 - Article

C2 - 17873754

AN - SCOPUS:34548684111

VL - 45

SP - 370

EP - 391

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 3

ER -